This work was supported in part by awards from the Department of Veteran’s Affairs MERIT Award BX002286;the Innovative Research Award from the Rheumatology Research Foundation(RRF);the National Institutes of Health NIH AI147697;the National Psoriasis Foundation(NPF);the Pfizer Investigator-Initiated Research(IIR)Program;the Chicago Biomedical Consortium(CBC)Accelerator Award.
IL-34 is a novel biomarker for rheumatoid arthritis(RA),as its serum levels are linked to C-reactive protein,erythrocyte sedimentation rate,rheumatoid factor(RF),IL-6 and radiographic progression[1,2].IL-34 reprograms...